Avidity Partners Management’s Dianthus Therapeutics DNTH Stock Holding History

Avidity Partners Management’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$205M	Hold	2,104,184	–	–	32.85%	1
2026 Q1	$177M	Hold	2,104,184	–	–	35.76%	1
2025 Q4	$86.7M	Sell	2,104,184 -1,100,000	-34%	-$42.6M	25.01%	1
2025 Q3	$126M	Buy	3,204,184 +1,461,282	+84%	+$37.3M	28.7%	1
2025 Q2	$32.5M	Buy	1,742,902 +22,000	+1%	+$413K	6.47%	4
2025 Q1	$31.2M	Sell	1,720,902 -1,152,098	-40%	-$25.4M	5.95%	2
2024 Q4	$62.6M	Sell	2,873,000 -44,231	-2%	-$1.14M	6.15%	1
2024 Q3	$79.9M	Hold	2,917,231	–	–	4.07%	2
2024 Q2	$75.5M	Buy	2,917,231 +199,677	+7%	+$4.8M	3.21%	6
2024 Q1	$81.5M	Buy	2,717,554 +1,500,000	+123%	+$32.6M	2.63%	6
2023 Q4	$12.7M	Hold	1,217,554	–	–	0.46%	57
2023 Q3	$16.6M	Buy	+1,217,554	New	+$15.3M	0.67%	56

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Avidity Partners Management's DNTH Position: Q2 2026 in Review

Avidity Partners Management held its Dianthus Therapeutics (DNTH) position steady in Q2 2026 at 2,104,184 shares worth $205M. The position accounts for 32.85% of the portfolio, ranked #1.

Avidity Partners Management first reported a position in DNTH in Q3 2023 and has held it in 12 quarters since. 269 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

Avidity Partners Management held 2,104,184 shares of Dianthus Therapeutics worth $205M as of Q2 2026.
Avidity Partners Management left its Dianthus Therapeutics share count unchanged in Q2 2026.
Dianthus Therapeutics made up 32.85% of Avidity Partners Management's portfolio in Q2 2026, its #1 holding.
Avidity Partners Management first reported a position in Dianthus Therapeutics in Q3 2023 and has held it in 12 quarters since.
269 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Avidity Partners Management's 13F filing for Q2 2026, filed 14 Aug 2026.